Market Report: A Look at Longevity in 2026

January 31, 2026

Longevity and anti-senescence therapy — medical and scientific approaches designed to extend human lifespan and promote healthy aging by targeting the biological processes that cause aging, cellular damage, and decline in bodily functions — are having more than a moment right now. The industry is on an upward swing, ready to expand from nearly $800 billion to an expected $1,868.2 billion by 2034. That’s a projected compound annual growth rate of approximately 8.2%, driven by products, services, and technologies designed to reverse senescence, the process where cells lose the ability to divide and function properly, and mitigate aging and age-related diseases.

The benefits of the longevity industry are twofold: it provides opportunities to investors and health care practitioners while enhancing and expanding health and quality of life for patients. Let’s take a look at what the market has to say.

Continue reading →

Destigmatizing Hormone Replacement Therapy, Improving Women’s Health

January 23, 2026

An evolution in menopausal hormone therapy (MHT) is officially underway. New interpretations of safety data from randomized trials and observational studies have resulted in the Food and Drug Administration (FDA)’s decision to remove the class-wide black box warnings for many systemic estrogen and combined estrogen-progestogen (EPT) products, and experts in women’s health are advocating to remove the barriers and improve access to MHT.

Life-Changing Medication

Throughout the human body, hormones support physical, mental, and metabolic health. As hormone levels decline with age, the risk of arthritis, heart disease, cancer, diabetes, and other chronic conditions rises, and many women experience the symptoms of menopause and perimenopause, including hot flashes, insomnia, and brain fog. HRT provides women with bioidentical estrogen and sometimes progesterone, but a controversial Women’s Health Initiative study in 2002 suggested that the therapies raise the risk of breast cancer, putting an end to HRT’s widespread use in the U.S.

Continue reading →

2026: The Year of Cognitive Longevity

January 17, 2026

Human beings have been chasing longevity since the days of Herodotus in ancient Greece. What’s changed since then is that living longer is now a reality, driven by a combination of modern medicine, biotechnology, science, and public health. Today’s advances in cardiovascular care, oncology, infectious disease, and metabolic management would have astonished the ancient Greek philosopher known as the Father of History, who chronicled tales of a “fountain of youth” in 450 BCE, and the extended lifespans we enjoy today — 86.5 is the average in top-rated Monaco, 79.5 in the US — would have been unimaginable.

Modern longevity experts want more. Advances in cardiovascular prevention, cancer therapy, infectious disease control, and metabolic management have dramatically reduced early mortality and extended lifespan across populations, but the concept of cognitive longevity is increasingly being added to the human wish list. Not only do humans want to live longer, but we want to do so without the progressive cognitive decline that too often goes hand in hand with aging.

Continue reading →